NDA 019763 · Baxter Hlthcare
Ifex/Mesnex Kit
Ifosfamide, Mesna · Injection · Alkylating Drug
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1987
Aug 14, 1987
Approved uses
1
Original approval plus efficacy supplements
Registered trials
517
121 Phase 3, 52 recruiting
FAERS reports
21,791
21,243 serious, 4,473 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: MYELOSUPPRESSION, ENCEPHALOPATHY, NEPHROTOXICITY and UROTOXICITY • Myelosuppression can be severe and lead to fatal infections. Monitor blood counts prior to and at intervals after each treatment cycle [see Warnings and Precautions (5.1) ]. • Encephalopathy can be severe and may result in death. Monitor for CNS toxicity and discontinue treatment for encephalopathy [see Warnings and Precautions (5.2) ]. • Nephrotoxicity can be severe and result in renal failure. Hemorrhagic cystitis can be severe and can be reduced by the prophylactic use of mesna [see Warnings and Precautions (5.3) ]. WARNING: MYELOSUPPRESSION, ENCEPHALOPATHY, NEPHROTOXICITY and UROTOXICITY See full prescribing information for complete boxed warning . • Myelosuppression can be severe and lead to fatal infections ( 5.1 ) • Encephalopathy can be severe and may result in death ( 5.2 ) • Nephrotoxicity can be...
What it is approved for
From the label in effect Oct 7, 2026.
Ifosfamide for Injection is indicated for use in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer. Ifosfamide for Injection is an alkylating drug indicated for use in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer. ( 1 )
Mechanism: Ifosfamide is a prodrug that requires metabolic activation by hepatic cytochrome P450 isoenzymes to exert its cytotoxic activity. Activation occurs by hydroxylation at the ring carbon atom forming the unstable intermediate 4‑hydroxyifosfamide and its ring-opened aldo tautomer, which decomposes to yield the cytotoxic and urotoxic compound acrolein and an alkylating isophosphoramide mustard isophosphoramide mustard. The exact mechanism of action of ifosfamide has not been determined, but its cytotoxic action is primarily through DNA crosslinks caused by alkylation by the isophosphoramide...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 14, 1987 Original approval · Type 1 - New Molecular Entity · priority review
4 products under this application
- IFEX/MESNEX KIT · IFOSFAMIDE 1GM/VIAL; MESNA 100MG/ML · INJECTABLE, INJECTION · Discontinued
- IFEX · IFOSFAMIDE 1GM/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- IFEX/MESNEX KIT · IFOSFAMIDE 3GM/VIAL; MESNA 100MG/ML · INJECTABLE, INJECTION · Discontinued
- IFEX · IFOSFAMIDE 3GM/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Ifosfamide" as an intervention, any sponsor and status, largest first.
- International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT01117441 · 6,136 participants · Start Jun 2010 · Primary completion Dec 31, 2021
Drug: PEG-L-asparaginase; cyclophosphamide and 14 more · For: Leukemia
Sites: Randwick, Australia; Westmead, Australia; Dornbirn, Austria · 139 sites in all
- Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017Pivotal-lookingRecruiting
Martin SchrappeAcademic, hospital or other
NCT03643276 · 5,000 participants (planned) · Start Jul 15, 2018 · Primary completion Jul 14, 2028
Drug: Blinatumomab; Bortezomib and 17 more · For: Acute Lymphoblastic Leukemia, Pediatric
Sites: Sydney, Australia; Westmead, Australia; Graz, Austria · 115 sites in all
- Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT00430118 · 4,559 participants · Start Jul 2000 · Primary completion Jan 2012
Drug: asparaginase; cyclophosphamide and 12 more · For: Leukemia
Sites: Dornbirn, Austria; Feldkirch-Tisis, Austria; Graz, Austria · 76 sites in all
- Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic LeukemiaPivotal-lookingStatus unknown
University Hospital, MotolAcademic, hospital or other
NCT00764907 · 4,000 participants (planned) · Start Nov 2002 · Primary completion Oct 2007
Drug: asparaginase; cyclophosphamide and 13 more · For: Leukemia
Sites: Prague, Czechia
- Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
Associazione Italiana Ematologia Oncologia PediatricaAcademic, hospital or other
NCT00613457 · 2,039 participants · Start Sep 2000 · Primary completion Jul 2006
Drug: dexamethasone; asparaginase and 13 more · For: Leukemia
- Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung CancerPivotal-lookingStatus unknown
National Cancer Institute (NCI)NIH
NCT00003240 · 1,800 participants (planned) · Start Oct 1995
Drug: cisplatin; ifosfamide and 4 more · For: Lung Cancer
Sites: London, United Kingdom
- FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcomaPivotal-lookingRecruiting
University of BirminghamAcademic, hospital or other
NCT04625907 · 1,672 participants (planned) · Start Sep 17, 2020 · Primary completion Jun 2030
Drug: Irinotecan; Actinomycin D and 7 more · For: Rhabdomyosarcoma
Sites: Brisbane, Australia; Camperdown, Australia; Clayton, Australia · 128 sites in all
- Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With OsteosarcomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00134030 · 1,334 participants · Start Nov 14, 2005 · Primary completion Jan 31, 2015
Drug: Cisplatin; Doxorubicin Hydrochloride and 4 more · For: Localized Osteosarcoma; Metastatic Osteosarcoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 218 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,896
- febrile neutropenia2,740
- disease progression2,145
- neutropenia1,931
- drug ineffective1,626
- thrombocytopenia1,578
- anaemia1,277
- pyrexia1,028
- product use in unapproved indication964
- sepsis888
- pancytopenia836
- infection822
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 208 |
| 2005 | 200 |
| 2006 | 145 |
| 2007 | 219 |
| 2008 | 236 |
| 2009 | 249 |
| 2010 | 284 |
| 2011 | 580 |
| 2012 | 686 |
| 2013 | 514 |
| 2014 | 410 |
| 2015 | 893 |
| 2016 | 843 |
| 2017 | 1,169 |
| 2018 | 1,263 |
| 2019 | 1,448 |
| 2020 | 1,833 |
| 2021 | 1,630 |
| 2022 | 2,092 |
| 2023 | 2,275 |
| 2024 | 1,896 |
| 2025 | 1,561 |
| 2026 | 1,155 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Current · updated Nov 18, 2026
IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01).
Current · updated Nov 18, 2026
Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01).
Current · updated Nov 18, 2026
IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01).
Current · updated Nov 18, 2026
Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02).
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Ifex* (Ifosfamide*) · HCPCS J9208
2024 spending
$46K
Beneficiaries
67
446 claims
Per beneficiary
$689
2024 ASP limit $25.96 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $119,274 |
| 2021 | $124,012 |
| 2022 | $77,067 |
| 2023 | $58,705 |
| 2024 | $46,148 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I, Verweij J, Gelderblom H, et al. · Lancet Oncol 2014 · Clinical Trial, Phase III, Comparative Study
- A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.
Pervaiz N, Colterjohn N, Farrokhyar F, et al. · Cancer 2008 · Meta-Analysis, Systematic Review
- Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.
Marina NM, Smeland S, Bielack SS, et al. · Lancet Oncol 2016 · Clinical Trial, Phase III, Comparative Study
- Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review.
Vazirian F, Samadi S, Rahimi H, et al. · Cancer Chemother Pharmacol 2022 · Systematic Review
- Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Brennan B, Kirton L, Marec-Bérard P, et al. · Lancet 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
- Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
Gaspar N, Occean BV, Pacquement H, et al. · Eur J Cancer 2018 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Baxter Hlthcare · Also marketed as Ifex
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.